Menu
The Study Drug
What is the study drug, RLY-4008?
RLY-4008 is a capsule taken daily by mouth. It is designed to target and stop proteins that form incorrectly because of the FGFR2 alteration. Researchers at Relay Therapeutics want to learn if RLY-4008 shows early signs of anti-tumor activity and may be a treatment option for people with cancer who have an FGFR2 alteration.
Will I receive the RLY-4008 if I join the study?
No participant will receive a placebo; every individual who qualifies and decides to participate in the study will receive the study drug.
What is an “investigational drug?”
The study drug, RLY-4008, is an investigational drug. The U.S. Food and Drug Administration (FDA) defines an investigational drug as a new drug that is administered to patients through a clinical study. A “investigational drug” refers to a drug that is not yet commercially available to patients or health care providers.
